Treating juvenile idiopathic arthritis to target: recommendations of an international task force

@article{Ravelli2018TreatingJI,
  title={Treating juvenile idiopathic arthritis to target: recommendations of an international task force},
  author={Angelo Ravelli and Alessandro Consolaro and Gerd Horneff and Ronald M. Laxer and Daniel J Lovell and Nico M Wulffraat and Jonathan D. Akikusa and Sulaiman M. Al-Mayouf and Jordi Ant{\'o}n and Tadej Av{\vc}in and Roberta A. Berard and Michael W. Beresford and Rub{\'e}n Burgos-Vargas and Rolando Cimaz and Fabrizio De Benedetti and Erkan Demirkaya and Dirk Foell and Yasuhiko Itoh and Pekka Lahdenne and Esi M. Morgan and Pierre Quartier and Nicolino Ruperto and Ricardo A. Russo and Claudia Saad-Magalh{\~a}es and Sujata Sawhney and Christiaan Scott and Susan Shenoi and Joost F Swart and Yosef Uziel and Sebastiaan J. Vastert and Josef S. Smolen},
  journal={Annals of the Rheumatic Diseases},
  year={2018},
  volume={77},
  pages={819 - 828}
}
Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an achievable goal for most patients. Reaching this target leads to improved outcomes. The objective was to develop recommendations for treating JIA to target. A Steering Committee formulated a set of recommendations based on evidence derived from a systematic literature review. These were subsequently discussed, amended and voted on by an international Task Force of 30 paediatric rheumatologists in a… Expand
Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals?
TLDR
In conclusion, a joint treat to target (T2T) strategy is a promising approach for JIA, however, implementation of T2T needs to capture more than just inactive disease. Expand
Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis
TLDR
It is hypothesized that a guided treat-to-target (T2T) approach is superior to routine care in polyarticular juvenile idiopathic arthritis (pJIA) in terms of reaching a clinical remission after 12 months of treatment. Expand
Consensus clinical approach for a newly diagnosed systemic juvenile idiopathic arthritis among members of the pediatric rheumatology Arab group
TLDR
This work provides a consensus guidance on the management of newly diagnosed sJIA patients among pediatric rheumatologists in Arab countries using a nominal group and Delphi-like techniques to form the final consensus. Expand
Advancing the treatment of juvenile idiopathic arthritis
Summary Treatment for juvenile idiopathic arthritis has undergone substantial changes in recent decades. These changes are partly due to the availability of new treatments, mainly biological agents,Expand
Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible?
TLDR
Remission can be achieved and sustained in (some) JIA patients, regardless of initial treatment, and future studies should focus on predictors (based on imaging-methods or biomarkers) for sustained drug-free remission and flare. Expand
Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind
TLDR
The low evidence base for the recommendations reflects a shortage of research specific to less resourced countries and serves as an impetus for further inquiry towards optimizing care for children with JIA around the world. Expand
The importance of transition from pediatric to adult rheumatology care in juvenile idiopathic arthritis
TLDR
An overview of the importance of transition in JIA is provided and important aspects such as expectations, maturation, disease characteristics, disease activity, adherence, disability, and psychological aspects among others have to be considered and addressed during the transition phase to improve self-esteem, self-assurance, and quality of life. Expand
Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis
TLDR
Implementation of structured disease activity monitoring and CDS in polyarticular JIA was associated with significant reductions in disease activity scores in both early and established disease. Expand
Juvenile Idiopathic Arthritis: An Overview for the Clinician
Juvenile idiopathic arthritis (JIA) is a diagnosis that applies to all forms of arthritis of unknown aetiology, they all have in common a chronic inflammatory process targeting the synovial membranesExpand
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations
TLDR
The similarities and differences between two sets of recommendations for the management of PsA are addressed and the implications for patient management are addressed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 85 REFERENCES
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
TLDR
The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA. Expand
Toward a treat-to-target approach in the management of juvenile idiopathic arthritis.
TLDR
A compelling argument is available at this time to suggest that the incorporation of treat-to-target approach in the management of children with JIA may improve disease outcome. Expand
Treating rheumatoid arthritis to target: recommendations of an international task force
TLDR
The 10 recommendations are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA based on evidence and expert opinion. Expand
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
TLDR
Treating-to-target-in-SLE (T2T/SLE) recommendations were developed by a large task force of multispecialty experts and a patient representative and it is anticipated that ‘treating- to-target’ can and will be applicable to the care of patients with SLE. Expand
Management of juvenile idiopathic arthritis: hitting the target
TLDR
How diverse forms of standardized, guideline-led care and personalized treatment can be combined into a targeted, patient-centred approach to optimize management strategies for patients with JIA is discussed. Expand
Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis.
TLDR
A multidisciplinary, evidence- and consensus-based treatment guideline for JIA is created based on a systematic literature analysis and three consensus conferences, allowing creating guidelines that may potentially improve the quality of care for children and adolescents with JIA. Expand
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
TLDR
The task force defined the treatment target for SpA as remission or, alternatively, low disease activity, being aware that the evidence base is not strong and needs to be expanded by future research. Expand
Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.
TLDR
Preliminary criteria for inactive disease and clinical remission on and off medication for use in select categories of juvenile idiopathic arthritis (JIA) are formulated using consensus formation techniques. Expand
Management of Juvenile Idiopathic Arthritis 2015: A Position Statement from the Pediatric Committee of the Canadian Rheumatology Association
TLDR
This advocacy statement emphasizes the importance of empowering children and their caregivers, facilitating early detection of JIA, prompt referral to a team of health professionals who are expert in the diagnosis and management of childhood rheumatic diseases, prompt access to all appropriate pharmacologic and biologic therapies, and regular followup and monitoring. Expand
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
TLDR
There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. Expand
...
1
2
3
4
5
...